Cyfuse Biomedical K.K.
4892 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 港区三田３−５−２７ 住友不動産三田ツインビル西館
- Website:
- https://en.cyfusebio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cyfuse Biomedical K.K. is a pioneering Japanese company specializing in innovative bioprinting technologies. Based in Tokyo with an additional office in Fukuoka, Cyfuse focuses on the development of advanced tissue engineering solutions, utilizing its proprietary 3D bioprinting platform. The company aims to revolutionize regenerative medicine by creating functional, living tissues for therapeutic applications, including drug testing and personalized medicine. With a commitment to research and development, Cyfuse Biomedical is at the forefront of transforming healthcare solutions and addressing critical challenges in tissue regeneration. Through its cutting-edge technology, Cyfuse is poised to make a significant impact on the future of medical treatments.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-30 08:30 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 924.1 KB | |
| 2025-03-26 03:03 |
Inside Information Statement
臨時報告書
|
Japanese | 21.4 KB | |
| 2025-03-26 03:02 |
Internal Control over Financial Reporting
内部統制報告書－第15期(2024/01/01－2024/12/31)
|
Japanese | 22.7 KB | |
| 2025-03-26 03:01 |
Annual Report
有価証券報告書－第15期(2024/01/01－2024/12/31)
|
Japanese | 2.2 MB | |
| 2025-03-26 03:01 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2025-02-25 08:30 |
Inside Information Statement
臨時報告書
|
Japanese | 20.6 KB | |
| 2024-08-14 08:33 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-08-14 08:32 |
Interim Report
半期報告書－第15期(2024/01/01－2024/12/31)
|
Japanese | 234.3 KB | |
| 2024-05-15 09:16 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-05-15 09:15 |
Quarterly Report
四半期報告書－第15期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 196.4 KB | |
| 2024-04-17 10:10 |
Inside Information Statement
臨時報告書
|
Japanese | 43.2 KB | |
| 2024-03-27 08:18 |
Inside Information Statement
臨時報告書
|
Japanese | 23.2 KB | |
| 2024-03-27 08:17 |
Internal Control over Financial Reporting
内部統制報告書－第14期(2023/01/01－2023/12/31)
|
Japanese | 22.8 KB | |
| 2024-03-27 08:16 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-03-27 08:15 |
Annual Report
有価証券報告書－第14期(2023/01/01－2023/12/31)
|
Japanese | 2.2 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |